Berg Nutrition Brings a Unique Form of Pure Capsaicin Called aXivite to U.S. Marketplace
28 juil. 2020 10h02 HE
|
Berg Nutrition
ANN ARBOR, Mich., July 28, 2020 (GLOBE NEWSWIRE) -- Berg Nutrition has been named the exclusive U.S. distributer of the branded ingredient, aXivite phenylcapsaicin, a synthetic, innovative form of...
Biotricity Launches Innovative Pain Management Product with NeuPath Health
10 mars 2020 08h00 HE
|
biotricity
REDWOOD CITY, Calif., March 10, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has launched its...
Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences
27 janv. 2020 07h00 HE
|
Sorrento Therapeutics, Inc.
Phase 1b/2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts. The program is expected to...
Adynxx Reports Third Quarter 2019 Financial Results
14 nov. 2019 06h00 HE
|
Adynxx, Inc.
SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
28 oct. 2019 07h57 HE
|
Aptinyx Inc.
Study met primary and secondary endpoints – statistically significant effects on neuroimaging biomarkers and patient-reported measures ePoster to be presented at ACR Annual Meeting on Tuesday,...
Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience
15 oct. 2019 08h46 HE
|
Aptinyx Inc.
EVANSTON, Ill., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
30 sept. 2019 07h03 HE
|
Aptinyx Inc.
EVANSTON, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925
26 sept. 2019 08h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors
04 sept. 2019 07h27 HE
|
Aptinyx Inc.
EVANSTON, Ill., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Endonovo Therapeutics Appoints Dr. Geoffrey Abrams of Stanford University to Its Scientific Advisory Board
30 août 2019 09h00 HE
|
Endonovo Therapeutics Inc.
LOS ANGELES, Aug. 30, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Endonovo Therapeutics Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of noninvasive Electroceutical®...